Page 1

Investor Relations | IDEAYA Biosciences IDEAYA Biosciences , Inc. Reports First Quarter 2021 Financial Results and Provides Business Update - Completed enrollment of initial dose escalation cohort of the Phase 1 clinical trial evaluating IDE397 , a potential best - in - class MAT2A inhibitor for MTAP - deletion patients - - Demonstrated IDE397 single - agent preclinical activity in a 40 - plus MTAP - deletion PDX study across major solid tumor types , including > 60 % TGI in 11 of 13 NSCLC PDX models , and tumor regressions in 2 of 4 NSCLC squamous PDX models , including a complete response Targeting development candidate nomination for potential first - in - class PARG and Pol Theta Synthetic Lethality programs in 2021 - Targeting FDA regulatory guidance in second half of 2021 based on preliminary darovasertib ( IDE196 ) monotherapy overall survival data ( OS ) of 57 % 1 - year OS and median OS of 13.2 months in predominantly 2L / 3L + MUM patients , where historical 1 - year OS and median OS is reported at 37 % and approximately 7 months , respectively , in a similar patient population Reported early partial responses of darovasertib plus binimetinib combination evaluated in Phase 1/2 clinical trial in predominantly 2L / 3L + MUM patients Observed early clinical efficacy in first cohort of darovasertib plus crizotinib combination with tumor reduction in 2 of 2 evaluable MUM patients , including a partial response in a 3L patient with a 54 % tumor reduction who is awaiting a confirmatory scan - Initiated darovasertib plus crizotinib combination Phase 1/2 dose expansion based on early clinical activity observed in first cohort ; additional dose exploration ongoing - Targeting clinical data update for darovasertib combination ( s ) in the second half of 2021 - Strong balance sheet of ~ $ 325 million cash , cash equivalents and marketable securities is anticipated to fund planned operations into 2024 SOUTH SAN FRANCISCO , Calif . , May 10 , 2021 / PRNewswire / -- IDEAYA Biosciences , Inc. ( Nasdaq : IDYA ) , a synthetic lethality focused precision medicine oncology company committed to the discovery and development of targeted therapeutics , provided a business update and announced financial results for the first quarter ended March 31 , 2021 . " We are excited to advance IDE397 , a potential best - in - class MAT2A inhibitor , in the Phase 1 dose escalation for evaluation in patients with MTAP deletion tumors , including in non - small cell lung cancer ( NSCLC ) . We are also continuing to invest in our preclinical synthetic lethality programs , including our PARG and Pol Theta programs for patients with HRD tumors , where we are targeting a development candidate for both programs in 2021 , " said Yujiro S. Hata , Chief Executive Officer and President of IDEAYA Biosciences . " We are excited by the preliminary darovasertib monotherapy overall survival data in MUM and look forward to receiving FDA regulatory guidance based on the data in the second half of 2021. We are also executing on our darovasertib clinical combination strategy and are encouraged by the early partial responses observed in the combination arms , including now in the crizotinib combination . Importantly , the 54 % tumor reduction by RECIST 1.1 observed in a patient treated with the darovasertib and crizotinib combination is the deepest partial response we have seen to date in the darovasertib Phase 1/2 clinical trial , " said Matthew Maurer , M.D. , Vice President , Head of Clinical Oncology and Medical Affairs , IDEAYA Biosciences . Program Updates Key highlights for IDEAYA's pipeline programs include : IDE397 ( MAT2A ) IDEAYA is evaluating IDE397 , a potent and selective small molecule inhibitor targeting methionine